• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Wednesday

    7/26/23 12:18:54 PM ET
    $ACGN
    $ACXP
    $ADMP
    $ADTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACGN alert in real time by email

     

    Wednesday saw 59 companies set new 52-week lows.

    Key Facts About Today's 52-Week Lows:

    • The largest company by market cap to hit a new 52-week low was TC Energy (NYSE:TRP).
    • China SXT Pharmaceuticals (NASDAQ:SXTC) was the smallest company by market cap to set a new 52-week low.
    • AppHarvest (NASDAQ:APPH)'s stock fell the most, as it traded down 19.83% to reach a new 52-week low.
    • XOMA (NASDAQ:XOMA)'s stock made the biggest bounce back, actually moving up 0.0% shortly after hitting a new 52-week low.

    Stocks dropping to new 52-week lows on Wednesday:

    • TC Energy (NYSE:TRP) shares were up 0.49% for the day, having made a 52-week low of $36.44.
    • Apellis Pharmaceuticals (NASDAQ:APLS) stock dropped to a yearly low on Wednesday of $29.70. Shares traded up 4.98%.
    • Cytokinetics (NASDAQ:CYTK) stock drifted up 0.34% on Wednesday morning to hit a new 52-week low of $31.81.
    • Maravai LifeSciences (NASDAQ:MRVI) shares moved down 2.18% on Wednesday to hit a new 52-week low of $11.38, drifting down 2.18%.
    • Monro (NASDAQ:MNRO) shares were down 2.67% for the day, having made a 52-week low of $37.25.
    • Avidity Biosciences (NASDAQ:RNA) shares made a new 52-week low of $8.93 on Wednesday. The stock was down 1.75% for the day.
    • Nexa Res (NYSE:NEXA) shares set a new 52-week low of $4.15. The stock traded up 1.18%.
    • Vertex Energy (NASDAQ:VTNR) shares made a new 52-week low of $4.84 on Wednesday. The stock was up 1.71% for the day.
    • Sharecare (NASDAQ:SHCR) shares were down 5.56% for the day, having made a 52-week low of $1.26.
    • uniQure (NASDAQ:QURE) shares hit a yearly low of $9.39. The stock was down 0.32% on the session.
    • PSQ Holdings (NYSE:PSQH) stock set a new 52-week low of $12.26 on Wednesday, moving down 12.69%.
    • Stoke Therapeutics (NASDAQ:STOK) stock set a new 52-week low of $5.90 on Wednesday, moving down 0.7%.
    • SWK Holdings (NASDAQ:SWKH) stock drifted up 0.12% on Wednesday morning to hit a new 52-week low of $16.07.
    • NGM Biopharmaceuticals (NASDAQ:NGM) stock hit $2.34 on Wednesday morning, setting a new 52-week low for a change of down 0.63%.
    • FibroGen (NASDAQ:FGEN) stock hit $1.84 on Wednesday morning, setting a new 52-week low for a change of down 5.33%.
    • XOMA (NASDAQ:XOMA) stock achieved a new 52-week low on Wednesday morning, hitting $15.26 and moving 0.0% (flat).
    • Complete Solaria (NASDAQ:CSLR) stock hit a yearly low of $4.56. The stock was down 6.12% for the day.
    • Altimmune (NASDAQ:ALT) stock dropped to a yearly low on Wednesday of $2.95. Shares traded up 0.33%.
    • Beyond Air (NASDAQ:XAIR) stock hit a new 52-week low of $3.44. The stock was down 1.0% on the session.
    • ARB IOT Group (NASDAQ:ARBB) stock broke to a new 52-week low of $2.25 on Wednesday. Shares of the company traded down 6.52%.
    • Carmell Therapeutics (NASDAQ:CTCX) stock achieved a new 52-week low on Wednesday morning, hitting $2.97 and moving down 14.93%.
    • Candel Therapeutics (NASDAQ:CADL) stock set a new 52-week low of $1.10 on Wednesday, moving down 0.88%.
    • Leap Therapeutics (NASDAQ:LPTX) stock set a new 52-week low of $2.54 on Wednesday, moving down 6.18%.
    • Aptose Biosciences (NASDAQ:APTO) stock hit $4.01 on Wednesday morning, setting a new 52-week low for a change of down 0.37%.
    • Gulf Resources (NASDAQ:GURE) shares set a new yearly low of $2.32 this morning. The stock was down 1.67% on the session.
    • Acurx Pharmaceuticals (NASDAQ:ACXP) stock hit a new 52-week low of $1.89. The stock was down 2.58% on the session.
    • Cosmos Health (NASDAQ:COSM) stock hit a new 52-week low of $1.66. The stock was 0.0% (flat) on the session.
    • BioCardia (NASDAQ:BCDA) stock hit a new 52-week low of $0.99. The stock was down 2.39% on the session.
    • Vaccinex (NASDAQ:VCNX) stock broke to a new 52-week low of $0.27 on Wednesday. Shares of the company traded up 0.18%.
    • Flora Growth (NASDAQ:FLGC) stock drifted down 2.56% on Wednesday morning to hit a new 52-week low of $2.05.
    • IronNet (NYSE:IRNT) shares moved down 2.58% on Wednesday to hit a new 52-week low of $0.11, drifting down 2.58%.
    • ShiftPixy (NASDAQ:PIXY) shares fell to $1.05 on Wednesday, setting a new 52-week low with a shift of down 3.39%.
    • 60 Degrees (NASDAQ:SXTP) stock hit a yearly low of $2.01. The stock was down 3.05% for the day.
    • Tempest Therapeutics (NASDAQ:TPST) stock hit a yearly low of $0.95. The stock was down 5.11% for the day.
    • Fangdd Network Group (NASDAQ:DUO) shares fell to $0.16 on Wednesday, setting a new 52-week low with a shift of down 4.35%.
    • Sidus Space (NASDAQ:SIDU) shares set a new 52-week low of $0.17. The stock traded down 4.53%.
    • Cyclerion Therapeutics (NASDAQ:CYCN) stock achieved a new 52-week low on Wednesday morning, hitting $2.95 and moving down 4.11%.
    • Bio-Path Hldgs (NASDAQ:BPTH) shares set a new 52-week low of $0.85. The stock traded down 4.04%.
    • Lixte Biotech Hldgs (NASDAQ:LIXT) stock set a new 52-week low of $3.59 on Wednesday, moving down 5.41%.
    • Mallinckrodt (AMEX:MNK) shares fell to $0.41 on Wednesday, setting a new 52-week low with a shift of up 12.72%.
    • Aceragen (NASDAQ:ACGN) stock hit a new 52-week low of $0.59. The stock was up 6.33% on the session.
    • Jeffs Brands (NASDAQ:JFBR) shares hit a yearly low of $0.65. The stock was down 1.6% on the session.
    • Adamis Pharmaceuticals (NASDAQ:ADMP) stock set a new 52-week low of $1.65 on Wednesday, moving up 0.26%.
    • Shineco (NASDAQ:SISI) stock broke to a new 52-week low of $0.22 on Wednesday. Shares of the company traded down 2.61%.
    • 180 Life Sciences (NASDAQ:ATNF) shares fell to $0.85 on Wednesday, setting a new 52-week low with a shift of down 12.75%.
    • Avalo Therapeutics (NASDAQ:AVTX) stock drifted up 4.87% on Wednesday morning to hit a new 52-week low of $0.21.
    • Salarius Pharmaceuticals (NASDAQ:SLRX) shares set a new yearly low of $0.85 this morning. The stock was down 1.15% on the session.
    • Aditxt (NASDAQ:ADTX) stock drifted up 0.5% on Wednesday morning to hit a new 52-week low of $0.39.
    • NeuBase Therapeutics (NASDAQ:NBSE) stock broke to a new 52-week low of $1.35 on Wednesday. Shares of the company traded down 1.36%.
    • First Wave BioPharma (NASDAQ:FWBI) stock achieved a new 52-week low on Wednesday morning, hitting $0.55 and moving down 2.44%.
    • Allarity Therapeutics (NASDAQ:ALLR) stock hit $2.78 on Wednesday morning, setting a new 52-week low for a change of up 0.71%.
    • Esports Entertainment (NASDAQ:GMBL) stock drifted down 5.32% on Wednesday morning to hit a new 52-week low of $0.47.
    • BitNile Metaverse (NASDAQ:BNMV) stock drifted down 5.68% on Wednesday morning to hit a new 52-week low of $0.80.
    • China SXT Pharmaceuticals (NASDAQ:SXTC) stock dropped to a yearly low on Wednesday of $0.17. Shares traded up 0.21%.

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $ACGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACGN
    $ACXP
    $ADMP
    $ADTX

    CompanyDatePrice TargetRatingAnalyst
    TC Energy Corporation
    $TRP
    4/23/2026Neutral → Sector Outperform
    CIBC
    Candel Therapeutics Inc.
    $CADL
    4/20/2026Overweight
    Cantor Fitzgerald
    TC Energy Corporation
    $TRP
    4/20/2026$62.00Sell → Neutral
    Goldman
    Cytokinetics Incorporated
    $CYTK
    4/10/2026$95.00Overweight
    Wells Fargo
    Avalo Therapeutics Inc.
    $AVTX
    4/9/2026$48.00Outperform
    Wolfe Research
    Nexa Resources S.A.
    $NEXA
    4/9/2026Underweight → Equal-Weight
    Morgan Stanley
    Avalo Therapeutics Inc.
    $AVTX
    4/6/2026$52.00Mkt Outperform
    Citizens
    Altimmune Inc.
    $ALT
    3/18/2026$12.00Buy
    Truist
    More analyst ratings

    $ACGN
    $ACXP
    $ADMP
    $ADTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 1, 2022 - FDA Roundup: July 1, 2022

    For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us

    7/1/22 11:54:25 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    FDA Approval for ZIMHI issued to ADAMIS PHARMS CORP

    Submission status for ADAMIS PHARMS CORP's drug ZIMHI (ORIG-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 10/15/2021. Application Category: NDA, Application Number: 212854, Application Classification: Type 5 - New Formulation or New Manufacturer

    10/18/21 11:55:40 AM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SYMJEPI issued to ADAMIS PHARMS CORP

    Submission status for ADAMIS PHARMS CORP's drug SYMJEPI (SUPPL-12) with active ingredient EPINEPHRINE has changed to 'Approval' on 06/29/2021. Application Category: NDA, Application Number: 207534, Application Classification: Labeling

    6/30/21 5:11:48 AM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $ACXP
    $ADMP
    $ADTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $24,061 worth of Class A Shares (72,912 units at $0.33) and sold $3,595 worth of Class A Shares (11,982 units at $0.30), increasing direct ownership by 100% to 121,592 units (SEC Form 4)

    4 - Aditxt, Inc. (0001726711) (Issuer)

    4/23/26 3:43:04 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Hrt Financial Lp claimed ownership of 133,574 units of Class A Shares (SEC Form 3)

    3 - Aditxt, Inc. (0001726711) (Issuer)

    4/23/26 3:37:12 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Kenney Stephanie

    4 - Atrium Therapeutics, Inc. (0002093101) (Issuer)

    4/22/26 5:54:12 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $ACXP
    $ADMP
    $ADTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PSQ Holdings Announces First Quarter 2026 Financial Results Release Date & Conference Call

    PSQ Holdings, Inc. (NYSE:PSQH) (the "Company"), today announced it will host a teleconference and webcast to discuss its first quarter 2026 results beginning at 9:00 a.m. EDT on Thursday, May 7, 2026. The Company will issue a news release containing first quarter 2026 results on May 7, 2026, before the U.S. stock market opens. The conference call can be accessed live through a link on the PSQ Holdings Investor Relations website at investors.publicsquare.com. During the webcast, the company will take both inbound questions received ahead of the call and questions from equity research analysts. Questions may be submitted starting April 30, 2026, through the Say Technologies platform at app.

    4/23/26 4:15:00 PM ET
    $PSQH
    Advertising
    Consumer Discretionary

    Sidus Space Advances its Fortis Next-Generation Command and Data Handling (C&DH) System

    Microchip collaboration enables accelerated, modular, and mission‑scalable OpenVPX architectures for space and defense applications CAPE CANAVERAL, Fla., April 23, 2026 /PRNewswire/ -- Sidus Space, Inc. (NASDAQ:SIDU) ("Sidus" or the "Company"), an innovative space and defense technology company, today announced continued advancements to its Fortis Command and Data Handling (C&DH) platform, a modular 3U OpenVPX system designed to support rapid development, configuration flexibility, and long-term scalability across next-generation space and defense missions. Supported by a strate

    4/23/26 8:31:00 AM ET
    $SIDU
    Telecommunications Equipment
    Telecommunications

    Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

    SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from Bristol Myers Squibb (NYSE:BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration. "This milestone marks a meaningful step forward for Atrium, further expanding our RNA deliv

    4/23/26 8:00:00 AM ET
    $BMY
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $ACXP
    $ADMP
    $ADTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $24,061 worth of Class A Shares (72,912 units at $0.33) and sold $3,595 worth of Class A Shares (11,982 units at $0.30), increasing direct ownership by 100% to 121,592 units (SEC Form 4)

    4 - Aditxt, Inc. (0001726711) (Issuer)

    4/23/26 3:43:04 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Weaver Gregory L bought $17,700 worth of shares (5,000 units at $3.54), increasing direct ownership by 22% to 28,078 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:05:04 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Durso Jerome Benedict bought $70,790 worth of shares (20,000 units at $3.54), increasing direct ownership by 160% to 32,500 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:00:05 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $ACXP
    $ADMP
    $ADTX
    SEC Filings

    View All

    SEC Form S-8 filed by PSQ Holdings Inc.

    S-8 - PSQ Holdings, Inc. (0001847064) (Filer)

    4/23/26 5:25:13 PM ET
    $PSQH
    Advertising
    Consumer Discretionary

    SEC Form 424B3 filed by Aditxt Inc.

    424B3 - Aditxt, Inc. (0001726711) (Filer)

    4/23/26 4:30:42 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3MEF filed by Altimmune Inc.

    S-3MEF - Altimmune, Inc. (0001326190) (Filer)

    4/22/26 9:15:33 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $ACXP
    $ADMP
    $ADTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TC Energy upgraded by CIBC

    CIBC upgraded TC Energy from Neutral to Sector Outperform

    4/23/26 11:56:01 AM ET
    $TRP
    Natural Gas Distribution
    Utilities

    Cantor Fitzgerald initiated coverage on Candel Therapeutics

    Cantor Fitzgerald initiated coverage of Candel Therapeutics with a rating of Overweight

    4/20/26 8:26:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TC Energy upgraded by Goldman with a new price target

    Goldman upgraded TC Energy from Sell to Neutral and set a new price target of $62.00

    4/20/26 8:21:38 AM ET
    $TRP
    Natural Gas Distribution
    Utilities

    $ACGN
    $ACXP
    $ADMP
    $ADTX
    Leadership Updates

    Live Leadership Updates

    View All

    Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

    Adds dedicated business development leadership to support Tempest's strategic prioritiesWill lead China outreach and cross-border partnership effortsTo support ongoing partnering discussions for Phase 3-ready amezalpat program, including potential China development opportunities BRISBANE, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced the appointment of Andrew Fang, Ph.D., as Head of Business Development. Dr. Fang will lead Tempest's global business development efforts, including strategic partners

    4/14/26 8:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PSQ Holdings Announces Finance Leadership Transition

    James Rinn to step down as CFO, effective April 30, 2026, and will remain a member of the Board of Directors Michael Pena named Chief Financial Officer & Treasurer, effective May 1, 2026 Krista Wenzel named Chief Accounting Officer, effective May 1, 2026 PSQ Holdings, Inc. (NYSE:PSQH) (the "Company"), announced today that James Rinn, Chief Financial Officer (CFO), has resigned from his role, effective April 30, 2026, to pursue another opportunity. Mr. Rinn will remain a Class III Director after stepping down as CFO. Following Mr. Rinn's departure, effective May 1, 2026, Michael Pena, current Senior Vice President of Finance for the Company, has been named Chief Financial Officer a

    4/7/26 4:15:00 PM ET
    $PSQH
    Advertising
    Consumer Discretionary

    Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced the appointment of Clare Kahn, Ph.D., to its Board of Directors. "Clare brings more than three decades of industry experience, and we are very pleased to welcome her to the Board at this pivotal time for Stoke," said Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics. "Clare's deep regulatory strategy and drug development expertise, p

    4/7/26 4:01:00 PM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ACGN
    $ACXP
    $ADMP
    $ADTX
    Financials

    Live finance-specific insights

    View All

    PSQ Holdings Announces First Quarter 2026 Financial Results Release Date & Conference Call

    PSQ Holdings, Inc. (NYSE:PSQH) (the "Company"), today announced it will host a teleconference and webcast to discuss its first quarter 2026 results beginning at 9:00 a.m. EDT on Thursday, May 7, 2026. The Company will issue a news release containing first quarter 2026 results on May 7, 2026, before the U.S. stock market opens. The conference call can be accessed live through a link on the PSQ Holdings Investor Relations website at investors.publicsquare.com. During the webcast, the company will take both inbound questions received ahead of the call and questions from equity research analysts. Questions may be submitted starting April 30, 2026, through the Say Technologies platform at app.

    4/23/26 4:15:00 PM ET
    $PSQH
    Advertising
    Consumer Discretionary

    Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

    SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from Bristol Myers Squibb (NYSE:BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration. "This milestone marks a meaningful step forward for Atrium, further expanding our RNA deliv

    4/23/26 8:00:00 AM ET
    $BMY
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics to Announce First Quarter Results on May 5, 2026

    SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report first quarter results on May 5, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics' website at www.cytokinetics.com or directly at the following link: Cytokinetics Q1 2026 Earnings Conference Call. An archived replay of the webcast will be available via Cytokinetics' websi

    4/21/26 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $ACXP
    $ADMP
    $ADTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

    SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

    12/17/24 8:02:53 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

    SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

    12/17/24 8:01:40 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care